替普瑞酮联合雷贝拉唑治疗慢性胃炎的效果分析  

Effect Analysis of Teprenone Combined with rabeprazole in the treatment of chronic gastritis

作　　者：李瑜斐[1] Li Yufei(Department of Gastroenterology,Shenyang Red Cross Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市红十字会医院消化内科,辽宁沈阳110000

出　　处：《中国医药指南》2020年第33期144-145,共2页Guide of China Medicine

摘　　要：目的分析替普瑞酮联合雷贝拉唑治疗慢性胃炎的临床效果。方法选取本院收治的108例慢性胃炎患者,采用红蓝双色球法将其分成两组各54例,对照组采用替普瑞酮(50 mg,口服,每日3次)治疗,观察组在此基础上采用雷贝拉唑(20 mg,口服,每日3次)治疗,14 d后比较两组的治疗效果及不良反应发生情况。结果观察组患者上腹疼痛时间(5.68±1.39)d、腹胀消失时间(5.31±1.51)d和反酸消失时间(5.46±1.16)d明显短于对照组的(9.57±1.64)d、(9.46±1.73)d和(9.29±1.28)d(P<0.05);观察组治疗有效率(96.30%)高于对照组(81.48%)(P<0.05);观察组为不良反应发生率为5.56%,对照组(11.11%),差异无统计学意义(P>0.05)。结论替普瑞酮联合雷贝拉唑治疗慢性胃炎能够有效缩短患者临床症状消失时间,提升治疗效果,安全性可靠。Objective To analyze the clinical effects of teprenone combined with rabeprazole in the treatment of chronic gastritis.Methods One hundred and eight patients with chronic gastritis admitted to our hospital were divided into two groups according to the red and blue two-color ball method.The control group was treated with teprenone(50 mg,oral,3 times a day),the observation group was used rabeprazole on this basis(20 mg,oral,3 times a day),14 days later compared the treatment effect and adverse reactions of the two groups.Results In the observation group,the time of upper abdominal pain(5.68±1.39)days,the time of disappearance of abdominal distension(5.31±1.51)days and the time of disappearance of acid reflux(5.46±1.16)days were significantly shorter than those of the control group(9.57±1.64)days,(9.46±1.73)days and(9.29±1.28)days(P<0.05);the effective rate of treatment in the observation group(96.30%)was higher than that in the control group(81.48%)(P<0.05);the incidence of adverse reactions in the observation group was 5.56%,and in the control group(11.11%),the difference was not statistically significant(P>0.05).Conclusion Teprenone combined with rabeprazole in the treatment of chronic gastritis can effectively shorten the disappearance of clinical symptoms,improve the therapeutic effect,and be safe and reliable.

关 键 词：慢性胃炎 替普瑞酮 雷贝拉唑 安全性 

分 类 号：R573.3[医药卫生—消化系统]